Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV
Withdrawn
National Institute of Allergy and Infectious Diseases (NIAID)
N/A
1969-12-31
This study will evaluate the drug telbivudine (LdT) for treatment of hepatitis B virus (HBV)
in HIV infected patients. Patients will take telbivudine alone for 24 weeks, add anti-HIV
drugs for 24 weeks, then stop taking telbivudine while continuing their anti-HIV drug
regimen. To enroll in this study, patients must not be taking any anti-HIV drugs and cannot
have taken more than 31 days of treatment with lamivudine (3TC), protease inhibitors (PIs),
or nonnucleoside reverse transcriptase inhibitors (NNRTIs).
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
Completed
Novartis Pharmaceuticals
Phase 3
2003-02-01
This study is being conducted to compare the safety and effectiveness of the investigational
medication, LdT (Telbivudine) with Lamivudine, a drug currently approved by the US, European
and Asian Health Authorities for the treatment of hepatitis B infection. The results for
patients taking LdT will be compared to results for patients taking Lamivudine.
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
Completed
Novartis
Phase 3
2003-02-01
This study is being conducted to compare the safety and effectiveness of the investigational
medication, LdT (Telbivudine) with Lamivudine, a drug currently approved by the US, European
and Asian Health Authorities for the treatment of hepatitis B infection. The results for
patients taking LdT will be compared to results for patients taking Lamivudine.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
